Enhanced circulation effector composition and method

• US 6,326,353 B1
• Filed: 03/23/1993
• Issued: 12/04/2001
• Est. Priority Date: 03/23/1993
• Status: Expired due to Term

• Current Assignee: SEQUUS Pharmaceuticals, Inc. (Johnson & Johnson)
• Original Assignee: SEQUUS Pharmaceuticals, Inc. (Johnson & Johnson)
• Inventors: Martin, Francis J., Zalipsky, Samuel, Barenholz, Yechezkel, Woodle, Martin C.
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US08/035,443
• Time in Patent Office: 3,178 Days
• Field of Search: 424/85.8, 424/450, 530/319, 530/812, 514/11
• US Class Current: 424/450
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/18 of the parathyroid hormones
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: Y10S 530/812 Peptides or proteins is immobilized on, or in, an organic carrier

Abstract

A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

Claims

1. In a method of treating a subject for septic shock by parenteral administration of polymyxin B, the improvement comprising

parenterally administering to the subject, a liposome composition containing liposomes having an outer layer of polyethylene glycol chains and said polymyxin B covalently attached to the distal ends of said chains.

2. The method claim 1, wherein the polyethylene glycol chains have a molecular weight between about 1,000 and 10,000 daltons.

3. A liposome composition for use in treating a subject for septic shock, comprising

liposomes, each having an outer layer of polyethylene glycol chains, and

polymyxin B attached to the distal ends of said chains.

4. The composition of claim 3, wherein the polyethylene glycol chains have a molecular weight between about 1,000 and 10,000 daltons.